Cybin (CYBN.NE) has selected social anxiety disorder (SAD) and generalized anxiety disorder (GAD) as the targets for their CYB004 proprietary psychedelic molecule. Cybin demonstrated their proof of concept for…
Latest News
Are stock markets about to crash hard?
Revive Therapeutics (RVV.CN) announces FDA acceptance of meeting request
Top 5 Gainers and Losers: LAC.TO, WEED.TO, OML.V
BC Bud Corp (BCBC.C) breathes new life into the cannabis space, up 3x in two months
Top 5 Gainers and Losers: TMQ.TO, GLM.CN, AGMR.V
Standard Uranium (STND.V) reports on exploration at Sun Dog Project